A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
出版年份 2018 全文链接
标题
A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
作者
关键词
-
出版物
Cancers
Volume 10, Issue 6, Pages 160
出版商
MDPI AG
发表日期
2018-05-28
DOI
10.3390/cancers10060160
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Expression of programmed death ligand 1 (PD-L1) in malignant and nonmalignant pancreatic tissue.
- (2017) Saqib Razzaque et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
- (2016) Karishma Rajani et al. MOLECULAR THERAPY
- Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma
- (2016) Anne M Noonan et al. MOLECULAR THERAPY
- The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer
- (2015) Devalingam Mahalingam et al. BMC CANCER
- Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors
- (2015) Miguel A. Villalona-Calero et al. CANCER
- Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma
- (2015) Douglas A. Rubinson et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity
- (2014) Fiona Errington et al. JOURNAL OF IMMUNOLOGY
- KRAS: feeding pancreatic cancer proliferation
- (2014) Kirsten L. Bryant et al. TRENDS IN BIOCHEMICAL SCIENCES
- Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation
- (2014) Shashi A. Gujar et al. Frontiers in Oncology
- Activated Ras Signaling Pathways and Reovirus Oncolysis: An Update on the Mechanism of Preferential Reovirus Replication in Cancer Cells
- (2014) Jun Gong et al. Frontiers in Oncology
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer
- (2013) J S Carew et al. Cell Death & Disease
- Systemic treatment of advanced pancreatic cancer
- (2012) Volker Heinemann et al. CANCER TREATMENT REVIEWS
- Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia
- (2012) Mitsuro Kanda et al. GASTROENTEROLOGY
- Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells
- (2012) Robert A. Adair et al. INTERNATIONAL JOURNAL OF CANCER
- Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples
- (2012) Gerard J Nuovo et al. MODERN PATHOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation
- (2011) D Pan et al. BRITISH JOURNAL OF CANCER
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
- (2010) M. P. Lolkema et al. CLINICAL CANCER RESEARCH
- Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity
- (2010) S. A. Gujar et al. MOLECULAR CANCER THERAPEUTICS
- Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication
- (2009) R. J. Prestwich et al. CLINICAL CANCER RESEARCH
- Reciprocal Human Dendritic Cell-Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus
- (2009) R. J. Prestwich et al. JOURNAL OF IMMUNOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
- (2008) L. Vidal et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now